EUVIMEDEUVIMED entdecken
Metaanalyse

A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran

Yihan Li, Kefan Xue, Rui Hu, Xiao Hu, Ran Guo, Hongxia Guo, Gang Li

American Journal of Cardiovascular Drugs · 2025

DOI: 10.1007/s40256-024-00702-z ↗

Kurz gefasst

Metaanalyse in der Zeitschrift American Journal of Cardiovascular Drugs, 2025. Verfasst von Yihan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Cholesterol, LDL, Proprotein Convertase 9. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Natural Science Foundation of Hebei Province, National Natural Science Foundation of China, the Medical Science Research Project of Hebei Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to systematically evaluate the regulation of low-density lipoprotein cholesterol (LDL-C) and proprotein convertase subtilisin-kexin type 9 (PCSK9) with inclisiran using a meta-analysis. METHODS: A comprehensive search of PubMed, Embase, the Cochrane Library, and Web of Science was conducted for randomized controlled trials of inclisiran published up to April 2024. Stata software was used for statistical analysis of outcome indicators from the included studies. Egger's test was employed to assess the risk of publication bias. RESULTS: A total of 10 studies involving 5208 participants were included in this meta-analysis. The results indicated that inclisiran significantly reduced LDL-C levels (weighted mean difference [WMD] - 48.17%; 95% confidence interval [CI] - 51.78 to - 44.56%; P < 0.01) and PCSK9 levels (WMD - 77.91%; 95% CI - 82.99 to - 72.84; P < 0.01) compared with the control group. The incidence of adverse reactions in the inclisiran group did not differ significantly from that in the placebo group (relative risk [RR] 1.03; 95% CI 0.99-1.09; P = 0.15). Similarly, there was no significant difference in the incidence of cardiovascular adverse events between the inclisiran and placebo groups (RR 0.92; 95% CI 0.74-1.16; P = 0.49). Sensitivity analysis showed that the exclusion of any single study did not significantly affect the final results. CONCLUSION: Current evidence suggests that inclisiran significantly lowers LDL-C and PCSK9 levels. The incidence of adverse events and cardiovascular adverse events was not significantly different from that with other drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsCholesterol, LDLProprotein Convertase 9HumansCardiovascular DiseasesRandomized Controlled Trials as TopicRNA, Small Interfering

Substanzen

ALN-PCSAnticholesteremic AgentsCholesterol, LDLPCSK9 protein, humanProprotein Convertase 9RNA, Small Interfering

Autor:innen und Institutionen

  • Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Division of Cardiology, Institute of Geriatric Diseases, Hebei General Hospital, Shijiazhuang, Hebei, China.
  • General Clinical Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Pathophysiology, Hebei Medical University, Shijiazhuang, Hebei, China.
  • Hebei Key Laboratory of Critical Disease Mechanism and Intervention, Shijiazhuang, Hebei, China.
  • The Third General Surgery Department, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

Förderung

  • Natural Science Foundation of Hebei Province
  • National Natural Science Foundation of China
  • the Medical Science Research Project of Hebei Provincial Health Commission
  • Hebei Province Government-Funded Clinical Medicine Excellent Talent Training Program

Zitieren

APA

Li, Y., Xue, K., Hu, R., Hu, X., Guo, R., Guo, H., & Li, G. (2025). A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-024-00702-z

Vancouver

Li Y, Xue K, Hu R, Hu X, Guo R, Guo H, et al. A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran. American Journal of Cardiovascular Drugs. 2025. doi:10.1007/s40256-024-00702-z

BibTeX
@article{Li2025,
  author = {Li, Yihan and Xue, Kefan and Hu, Rui and Hu, Xiao and Guo, Ran and Guo, Hongxia and Li, Gang},
  title = {A Meta-analysis of the Regulation of Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin-Kexin Type 9 with Inclisiran},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2025},
  doi = {10.1007/s40256-024-00702-z}
}
Kostenlos starten →